Blockade of c-Met-Mediated Signaling Pathways by E7050 Suppresses Growth and Promotes Apoptosis in...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• E7050 is a c-Met receptor tyrosine kinase inhibitor with potential anti-cancer applications.
• The precise molecular mechanisms underlying E7050's anti-cancer effects remain incompletely understood.

Purpose of the Study:

• To investigate the anti-tumor activity of E7050 against multidrug-resistant human uterine sarcoma MES-SA/Dx5 cells.
• To elucidate the molecular mechanisms responsible for E7050's anti-cancer properties in vitro and in vivo.

Main Methods:

• Cell viability assays, apoptosis assays, and cell cycle analysis were performed on MES-SA/Dx5 cells treated with E7050.
• Western blotting was used to assess the expression levels of key proteins involved in apoptosis, cell cycle regulation, and signaling pathways (c-Met, Src, Akt, p38).
• In vivo anti-tumor efficacy was evaluated in a xenograft mouse model using MES-SA/Dx5 cells, followed by immunohistochemical analysis of tumor tissues.

Main Results:

• E7050 significantly reduced MES-SA/Dx5 cell viability, induced apoptosis, and caused S phase cell cycle arrest.
• E7050 modulated the expression of apoptosis-related proteins (Bax, cleaved PARP, cleaved caspase-3), cell cycle regulators (p21, p53, cyclin D1, cyclin A), and survivin.
• Mechanistically, E7050 inhibited the phosphorylation of c-Met, Src, Akt, and p38 in response to HGF stimulation. In vivo, E7050 suppressed tumor growth, decreased Ki-67 and p-Met expression, and increased cleaved caspase-3 in tumor sections.

Conclusions:

• E7050 exhibits potent anti-tumor activity against multidrug-resistant uterine sarcoma by inducing apoptosis and cell cycle arrest.
• E7050 functions by inhibiting the c-Met signaling pathway and downstream effectors.
• E7050 represents a promising therapeutic candidate for the treatment of multidrug-resistant uterine sarcoma.